Your browser doesn't support javascript.
loading
Maybe we don't know JAK?
Schwarz, Luis J; Balko, Justin M.
Affiliation
  • Schwarz LJ; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University , Nashville, TN, USA.
  • Balko JM; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
Mol Cell Oncol ; 3(4): e1192713, 2016 Jul.
Article in En | MEDLINE | ID: mdl-27652332
ABSTRACT
The cornerstone for precision medicine is the development of robust biomarkers that reflect molecular phenotypes and therapeutic vulnerabilities in disease. We recently described Janus kinase-2 (JAK2)-specific inhibition as a therapeutic opportunity in triple negative breast cancers with 9p24 amplification. Here, we comment on this work and discuss the challenges of targeting this amplicon.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Cell Oncol Year: 2016 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Cell Oncol Year: 2016 Document type: Article Affiliation country: United States